- Home
- VIDA vs ELTX Comparison
VIDA vs ELTX Comparison
Compare VIDA & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VIDA | ELTX |
|---|---|---|
| Founded | 2022 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.7M | 63.3M |
| IPO Year | 2026 | 2014 |
Fundamental Metrics
Financial Performance| Metric | VIDA | ELTX |
|---|---|---|
| Price | $1.60 | $1.93 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $13.67 |
| AVG Volume (30 Days) | 110.6K | ★ 324.7K |
| Earning Date | 11-19-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,301,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.58 | $1.71 |
| 52 Week High | $4.25 | $16.00 |
Technical Indicators
Market Signals| Indicator | VIDA | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 32.83 | 23.58 |
| Support Level | N/A | $1.71 |
| Resistance Level | $2.79 | $3.32 |
| Average True Range (ATR) | 0.15 | 0.11 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 10.00 | 29.88 |
Price Performance
Historical ComparisonAbout ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.